RHU ORGANOMIC
RHU ORGANOMIC is a French academic-industrial consortium developing patient-derived organoid and microfluidic tumor-on-chip platforms to predict treatment response in digestive and lung cancers, funded by ANR and the France 2030 RHU program.
- Company typePrivate
- Founded2023
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What RHU ORGANOMIC does
RHU ORGANOMIC is a French academic-industrial consortium launched in April 2023 under the France 2030 RHU (Recherche Hospitalo-Universitaire) program, co-funded by ANR, to develop functional personalized medicine (fPM) platforms for digestive cancers and lung cancers. Its scientific approach combines patient-derived organoids (PDOs) cultured from patient tumors with microfluidic tumor-on-chip devices to test drug sensitivity and identify effective treatments within clinically actionable timeframes, reporting a 62% PDO success rate, 94% genomic concordance with the original tumor, and a roughly 6-week turnaround to treatment recommendation.
The consortium operates three research platforms: CHEMOGRAM for chemotherapy response profiling, IMMUNOGRAM for immunotherapy response, and INVAGRAM for tumor invasion and metastasis assessment. The microfluidic hardware is co-developed with Okomera (Cytobot / CytoReader), and AI/ML components — including convolutional neural networks for organoid image analysis and multimodal machine learning — are developed in-house at CentraleSupélec and jointly with ORAKL Oncology, AstraZeneca and Meta AI. Clinical validation is underway through two investigator-sponsored studies, ORGANOTREAT (Phase I-II, ~50 patients) and ORGANOPREDICT (18 patients across two cohorts).
The business model is grant-funded public research, not commercial product sales. Funding flows from ANR and the France 2030 RHU program; there is no disclosed pricing, no paying customer base, and no recurring revenue. Commercialization pathways — if any — would route through partner biotechs such as ORAKL Oncology or Okomera rather than through RHU ORGANOMIC itself. Governance sits with academic institutions including Gustave Roussy, INSERM, Institut Pasteur, Université Paris-Saclay, CentraleSupélec and Grenoble Ecole de Management, with the program coordinated by Fanny Jaulin alongside Michel Ducreux, Sandra Jernström, Charles Baroud and Paul-Henry Cournède.
RHU ORGANOMIC firmographics
Firmographics- Name
- RHU ORGANOMIC
- Legal name
- RHU ORGANOMIC
- Website
- https://rhu-organomic.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RHU ORGANOMIC is a French academic-industrial consortium developing patient-derived organoid and microfluidic tumor-on-chip platforms to predict treatment response in digestive and lung cancers, funded by ANR and the France 2030 RHU program.
- Ownership category
- akta.pro rank
RHU ORGANOMIC industry classification
Industry- Product category
- Functional Precision Medicine / Oncology Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
Keywords
Where RHU ORGANOMIC is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
RHU ORGANOMIC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Research Grant Funding: The consortium is funded by ANR (French National Research Agency) and France 2030 through a structured RHU (Hospital-University Research) grant. Revenue comes in the form of government research funding rather than commercial revenue generation.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
RHU ORGANOMIC product offering
Product offeringCore offering
RHU ORGANOMIC develops functional personalized medicine tests by combining patient-derived organoids (PDOs) with microfluidic tumor-on-chip devices to deliver two predictive devices (CHEMOGRAM and IMMUNOGRAM) and one prognostic device (INVAGRAM) for digestive and lung cancers. The platform is supported by two clinical trials (ORGANOTREAT and ORGANOPREDICT) and AI-based automated image analysis. It is a research consortium rather than a commercial product vendor, funded through French government grants.
Product overview
RHU ORGANOMIC is a research consortium developing a multi-device functional precision medicine platform centered on patient-derived organoids (PDOs). The platform combines PDOs with microfluidic tumor-on-chip technology and AI-powered image analysis to deliver three distinct diagnostic/prognostic devices: CHEMOGRAM (predictive drug sensitivity screening), IMMUNOGRAM (predictive immunotherapy response assessment), and INVAGRAM (prognostic disease progression monitoring) for digestive and lung cancers. The ecosystem includes two clinical trials (ORGANOTREAT and ORGANOPREDICT), automated organogram processing via deep learning algorithms, and standardized high-throughput read-outs using microscopy-based imaging and morphometry. All devices are designed to generate personalized treatment recommendations within clinically actionable timeframes.
Differentiator
Problem solved
Functional benefit
Products and services
- CHEMOGRAM A predictive diagnostic device combining patient-derived organoids (PDOs) with tumor-on-chip technology to screen anti-cancer drugs and identify effective treatments for individual patients with digestive and lung cancers.
- IMMUNOGRAM A predictive device that assesses PDO responses to immunotherapy by co-culturing PDOs with CAR-T cells or other immune cells to evaluate cytotoxicity and immune cell activity.
- INVAGRAM A prognostic device that analyzes patient-derived organoids to predict disease progression and patient outcomes in digestive and lung cancers.
- ORGANOTREAT Trial Clinical trial focused on orienting patient treatment using patient-derived organoid (PDO) functional testing to guide therapeutic decisions for advanced cancers.
- ORGANOPREDICT Trial Clinical trial focused on monitoring patient response to treatment using patient-derived organoid (PDO) functional testing for disease progression tracking.
- Tumor-on-Chip Platform Microfluidic device platform combining patient-derived organoids (PDOs) with high-throughput robotic drug screening capabilities for standardized, automated functional assessment of PDO responses to cancer therapies.
Quantifiable outcome
- 62% PDO generation success rate from pancreatic cancer patients
- +5 more outcomes
Companies that use RHU ORGANOMIC
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
RHU ORGANOMIC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature6 records
RHU ORGANOMIC partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Gustave RoussycoreGustave Roussy is a premier cancer research institute and one of Europe's leading oncology centers. They serve as a key clinical partner, hosting the ORGANOTREAT clinical trial and contributing expertise through Professor Michel Ducreux (Head of Digestive Oncology Department) and Dr. Alice Boilève.
- INSERMcoreFrench National Institute of Health and Medical Research, the leading French public research institute in biomedical research. Contributes scientific expertise and research infrastructure to the consortium.
- Institut PasteurcoreWorld-renowned French non-profit foundation dedicated to biological research. Charles Baroud's lab at Institut Pasteur has published significant research on cancer-on-chip models and T-cell engagement with cancer spheroids.
- Université Paris-SaclaycoreOne of the largest universities in Europe, providing research expertise and academic resources to the consortium. Contributes to clinical trials and PDO generation through WP2.
- CentraleSupéleccoreEngineering school affiliated with Université Paris-Saclay. Léo Fillioux from MICS at CentraleSupélec presented research on structured state space models for digital pathology at MICCAI 2023.
- AstraZenecaminorGlobal biopharmaceutical company focused on oncology research. Collaborates with the consortium on tumor-on-chip technology development and precision oncology initiatives.
- ORAKL OncologyminorOncology-focused company developing precision medicine solutions. Collaborates with Meta AI on applying DinoV2 foundation model to patient-derived tumor models. Contributes to tumor-on-chip designs and AI analysis.
- Grenoble Ecole de Management (GEM)minorTop French business school studying innovation management in healthcare. Researchers Dima Louis and Janna Rose examine how actors from different organizations collaborate, technology innovation evaluation, and social impact of technologies developed by the consortium.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
RHU ORGANOMIC competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
RHU ORGANOMIC social profiles
Digital presenceRHU ORGANOMIC financial estimates
Financial estimateRevenue estimate
Valuation estimate
RHU ORGANOMIC leadership team
Management profileNumber of profiles
Profiles5 records
RHU ORGANOMIC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RHU ORGANOMIC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RHU ORGANOMIC
What does RHU ORGANOMIC do?
RHU ORGANOMIC develops functional personalized medicine tests by combining patient-derived organoids (PDOs) with microfluidic tumor-on-chip devices to deliver two predictive devices (CHEMOGRAM and IMMUNOGRAM) and one prognostic device (INVAGRAM) for digestive and lung cancers. The platform is supported by two clinical trials (ORGANOTREAT and ORGANOPREDICT) and AI-based automated image analysis. It is a research consortium rather than a commercial product vendor, funded through French government grants.
Is RHU ORGANOMIC a public or private company?
RHU ORGANOMIC is a private company. It is classified as state government owned and is currently operating.
When was RHU ORGANOMIC founded?
RHU ORGANOMIC was founded in 2023. It employs 1 to 10 people.
Where is RHU ORGANOMIC based?
RHU ORGANOMIC is headquartered in Paris, France, in the Europe region.
How does RHU ORGANOMIC make money?
One revenue line is on record: research Grant Funding.
Does RHU ORGANOMIC have an API?
No public API is recorded for RHU ORGANOMIC.
What industry is RHU ORGANOMIC in?
RHU ORGANOMIC's product category is Functional Precision Medicine / Oncology Diagnostics. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAGAD, Organoids & Organ-on-Chip (regenerative models). Its NAICS code is 541714 and its SIC code is 2835.